Enliven Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
The company is advancing a highly specific BCR-ABL1 TKI for CML, with updated phase I data to be presented at EHA. Plans are in place for a pivotal second-line plus trial, with regulatory meetings expected mid-year and top-line data anticipated in early 2029. Cash reserves support operations through key milestones.
-
The company is advancing ELVN-001 for CML, with strong phase I data and a pivotal trial in second-line-plus CML planned for later this year. The drug shows a favorable safety and efficacy profile, is positioned to address resistance after asciminib, and has a cash runway into 2029.
-
ELVN-001 is advancing to phase 3 for CML, showing strong efficacy and safety in heavily pretreated patients. The company is well-funded, targeting a $9B US market, and plans to present updated data in June, with regulatory milestones expected by year-end.
Fiscal Year 2025
-
Focused on a selective ATP-competitive BCR-ABL inhibitor for CML, the team reports promising early efficacy in heavily pretreated patients and plans a large phase III trial next year. Rising resistance to allosteric TKIs and evolving treatment dynamics support their differentiated approach.
-
ELVN-001 demonstrated robust efficacy and favorable safety in heavily pretreated CML patients, with 47% achieving MMR by 24 weeks and low discontinuation rates. The drug's selectivity, convenient dosing, and strong safety profile support its advancement to pivotal trials targeting a broad CML population.
-
A late-line CML therapy shows promising efficacy and safety, with a pivotal study planned and a focus on optimal dosing. The company is considering a broader second line plus trial for greater commercial impact and maintains a strong cash position into late 2027.
-
ELVN-001 continues to show strong efficacy and tolerability in heavily pretreated CML patients, with upcoming EHA data expected to further validate its profile. Plans are underway for pivotal trials targeting both late- and earlier-line settings, while resources are being focused on ELVN-001 over ELVN-002.
-
The company is advancing two clinical-stage oncology assets, with ELVN-001 showing strong efficacy and safety in late-line CML and a major data update expected mid-2024. Plans are in place for a pivotal phase III trial, while strategic alternatives are being considered for ELVN-002.
Fiscal Year 2024
-
Significant advances in late-line CML treatment are underway, with new agents showing efficacy and safety comparable to or better than Scemblix, even in resistant patients. Upcoming phase III plans focus on broad labels and regulatory endpoints like 24-week MMR, leveraging strong market demand and evolving treatment paradigms.
-
Two lead oncology programs are advancing in phase 1, with ELVN-001 showing strong efficacy and safety in resistant CML and ELVN-002 targeting HER2-positive cancers with promising early data. Major data updates are expected in 2024 and 2025, guiding regulatory and strategic plans.
-
Two lead programs are advancing in CML and HER2-positive cancers, with ELVN-001 showing promising efficacy and safety in resistant CML patients. Major data updates and regulatory milestones are expected in 2025, with a strong cash position supporting ongoing development.